Over the past few decades, there has been a increasing prevalence of chronic diseases, live with a large number of people chronic diseases that may adversely affect them quality of life. The goal of the current work is to To investigate quality of life, particularly health-related quality of life (HRQoL) in patients with chronic diseases. HRQOL is a multidimensional structure It consists of at least three large domains − physical, mental and social functioning − affected by disease and/or treat. HRQoL usually starts with chronically ill and often impaired most. In addition, the following factors Also correlated with good and bad HRQoL Discussed as HRQoL assessment. That Estimating the relative impact of chronic diseases Necessary for HRQoL disease Better plan and allocate healthcare Resources to Improve HRQoLOver the past few decades, there has been a increasing prevalence of chronic diseases, live with a large number of people chronic diseases that may adversely affect them quality of life. The goal of the current work is to To investigate quality of life, particularly health-related quality of life (HRQoL) in patients with chronic diseases. HRQOL is a multidimensional structure It consists of at least three large domains − physical, mental and social functioning − affected by disease and/or treat. HRQoL usually starts with chronically ill and often impaired most. In addition, the following factors Also correlated with good and bad HRQoL Discussed as HRQoL assessment. That Estimating the relative impact of chronic diseases Necessary for HRQoL disease Better plan and allocate healthcare Resources to Improve HRQoL

Background: Fatigue is a typical consequence of cancer that can affect one's quality of life (QOL). The goal of this review is to provide comprehensive data on the impact of fatigue on QOL of cancer patients. Methods: An electronic data search in Web of Science, SCOPUS, and PubMed for relevant papers; those written in English; those reporting quantitative data; and those including more than one hundred patients who received just chemotherapy were included. Studies involving participants that received other kinds of anti-neoplastic therapies were excluded. Results: A total of 35 papers published between January 2000 and December 2021 were retrieved from the search databases of which (11612 patients) met the inclusion criteria. Findings showed that fatigue negatively affected QOL with a pooled prevalence of 49% (95% CI; 25.00-74.00) and the significant heterogeneity between articles was (I²=98%, P <0.001). Further, breast cancer contributed to the majority of selected articles with about 55 % (95%CI; 9:00-94:00), followed by cancer (unspecified) 44% (95%CI; 5:00 -92:00). Most studies (71%) (95%CI; 4:00 -99:00) used the brief fatigue inventory (BFI) tool to assess severity of fatigue and 39% (95%CI; 17:00 -68:00) employed the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire to evaluate QOL among cancer survivors. Conclusion: The prevalence of fatigue in cancer patients is high and fatigue has a negative impact on QOL of cancer patients receiving chemotherapy. Directionality, fatigue needs to be addressed and treated properly for better improvement of health status and QOL in cancer patients.

The antimalarial operators chloroquine and hydroxychloroquine have been utilized generally for the treatment of rheumatoid joint inflammation and fundamental lupus erythematosus. These mixes lead to progress of clinical and research facility parameters, however their moderate beginning of activity recognizes them from glucocorticoids and nonsteroidal mitigating operators. Chloroquine and hydroxychloroquine increment pH inside intracellular vacuoles and adjust procedures, for example, protein corruption by acidic hydrolases in the lysosome, get together of macromolecules in the endosomes, and posttranslation change of proteins in the Golgi mechanical assembly. It is suggested that the antirheumatic properties of these mixes results from their obstruction with "antigen preparing" in macrophages and other antigen-introducing cells. Acidic cytoplasmic compartments are required for the antigenic protein to be processed and for the peptides to collect with the alpha and beta chains of MHC class II proteins. Thus, antimalarials reduce the arrangement of peptide-MHC protein edifices required to animate CD4+ T cells and result in down-guideline of the safe reaction against autoantigenic peptides. Since this system varies from other antirheumatic drugs, antimalarials are appropriate to supplement these different mixes in blend medicate treatment[1].

(COVID-19) Finding a cure for Corona virus sickness in 2019 will be a difficult task for researchers all over the globe, since it is associated with significant lung damage and the potential for multiple organ failure. To far, dexamethasone has shown substantial benefits in COVID-19, reducing mortality while improving recovery. There is a reduction in inflammation due to a reduction in inflammation-related immune responses and a decrease in cytokine production, which prevents COVID-19 from becoming more severe. Dexamethasone's significance in the treatment of COVID-19 is currently unproven. When it comes to combating this pandemic, COVID-19's pathophysiology and dexamethasone's efficacy are the deciding factors.

Abstract:The study included a statistical collection of 100 cases during 2017 for women with urinary tract infections (UTI) in Al-Dahra Clinic -Ibn Sina Clinic -Aqabah Laboratory for Medical Analysis in Bani Waleed city-Libya. After determining the type of bacteria, we tested the antibiotics to eliminate the bacteria as soon as possible, as explained in the practical part First, the presence of bacteria in urine samples and we identified the type of bacteria and their proportion in the samples as shown in the following table (1). We have observed that increasing the bacterial resistance of our local isolates under study may be due to the large random use of antibiotics, which allowed for increased bacterial resistance to various antibiotics.